$SGMO
Sangamo Therapeutics Inc Stock $sgmo

$sgmo Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000162828019013510 Filed on November 06, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q4
Revenue	$54.85M	$21.96M	$26.84M
YoY Change	104.39%	-6.81%	105.22%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.05M	$14.92M	$12.26M
YoY Change	22.76%	35.76%	64.12%
% of Gross Profit
Research & Development	$38.33M	$36.29M	$33.25M
YoY Change	15.28%	25.96%	71.57%
% of Gross Profit
Depreciation & Amortization	$6.900M	$1.100M	$700.0K
YoY Change	885.71%	120.0%	40.0%
% of Gross Profit
Operating Expenses	$53.38M	$51.21M	$47.61M
YoY Change	12.13%	28.65%	77.36%
Operating Profit		-$29.25M
YoY Change		80.09%
Interest Expense	$3.030M	$1.890M	$1.550M
YoY Change	95.48%	-44.41%	127.94%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	$4.500M	-$27.36M	-$19.22M
YoY Change	-123.41%	113.08%	46.83%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	$4.555M	-$27.31M	-$18.66M
YoY Change	-124.41%	112.62%	42.57%
Net Earnings / Revenue	8.3%	-124.36%	-69.55%
Basic Earnings Per Share
Diluted Earnings Per Share	$39.33K	-$236.0K	-$182.5K
COMMON SHARES
Basic Shares Outstanding	115.9M shares	115.7M shares	102.1M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$362.5M	$354.9M	$400.1M
YoY Change	-9.41%	-22.62%	64.46%
Cash & Equivalents	$80.43M	$114.3M	$140.4M
Short-Term Investments	$282.0M	$240.6M	$259.7M
Other Short-Term Assets	$5.400M	$6.700M	$5.300M
YoY Change	1.89%	97.06%	253.33%
Inventory
Prepaid Expenses
Receivables	$36.91M	$21.95M	$4.673M
Other Receivables	$700.0K	$600.0K	$300.0K
Total Short-Term Assets	$405.5M	$384.2M	$410.5M
YoY Change	-1.23%	-17.95%	65.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$29.93M	$26.52M	$78.72M
YoY Change	-61.99%	-47.49%	153.41%
Goodwill	$39.27M	$38.27M	$40.04M
YoY Change	-1.93%	2314.51%	2426.44%
Intangibles	$53.16M	$51.74M	$54.24M
YoY Change	-2.0%
Long-Term Investments	$21.80M	$52.80M
YoY Change
Other Assets	$9.067M	$7.725M	$3.364M
YoY Change	169.53%	21.1%	184.84%
Total Long-Term Assets	$232.0M	$256.0M	$179.9M
YoY Change	29.0%	85.0%	369.14%
TOTAL ASSETS
Total Short-Term Assets	$405.5M	$384.2M	$410.5M
Total Long-Term Assets	$232.0M	$256.0M	$179.9M
Total Assets	$637.5M	$640.2M	$590.4M
YoY Change	7.98%	5.54%	105.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.671M	$19.00M	$3.355M
YoY Change	98.84%	15.85%	20868.75%
Accrued Expenses	$10.89M	$14.00M	$9.500M
YoY Change	14.58%	112.12%	72.73%
Deferred Revenue	$38.71M	$47.56M	$47.56M
YoY Change	-18.61%	-6.91%	67.8%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$69.87M	$80.55M	$78.51M
YoY Change	-11.0%	8.7%	75.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$5.711M	$5.542M	$1.960M
YoY Change	191.38%	220.35%	-93.29%
Total Long-Term Liabilities	$5.711M	$5.542M	$1.960M
YoY Change	191.38%	220.35%	-96.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$69.87M	$80.55M	$78.51M
Total Long-Term Liabilities	$5.711M	$5.542M	$1.960M
Total Liabilities	$204.8M	$220.9M	$223.1M
YoY Change	-8.23%	-2.56%	125.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$657.0M	-$661.5M	-$562.7M
YoY Change	16.76%		13.57%
Common Stock	$1.092B	$1.086B	$930.7M
YoY Change	17.34%		36.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$432.6M	$419.1M	$366.5M
YoY Change
Total Liabilities & Shareholders Equity	$637.5M	$640.2M	$590.4M
YoY Change	7.98%	5.54%	105.9%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q4
OPERATING ACTIVITIES
Net Income	$4.555M	-$27.31M	-$18.66M
YoY Change	-124.41%	112.62%	42.57%
Depreciation, Depletion And Amortization	$6.900M	$1.100M	$700.0K
YoY Change	885.71%	120.0%	40.0%
Cash From Operating Activities	-$20.80M	-$38.90M	-$39.50M
YoY Change	-47.34%	40.94%	135.12%
INVESTING ACTIVITIES
Capital Expenditures	-$6.800M	-$4.100M	-$28.10M
YoY Change	-75.8%	-55.43%	3022.22%
Acquisitions
YoY Change
Other Investing Activities	-$9.600M	-$12.10M	$90.90M
YoY Change	-110.56%	-113.15%	215.63%
Cash From Investing Activities	-$16.40M	-$16.20M	$62.80M
YoY Change	-126.11%	-119.57%	124.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.200M	700.0K	1.600M
YoY Change	-25.0%	-36.36%	-86.99%
NET CHANGE
Cash From Operating Activities	-20.80M	-38.90M	-39.50M
Cash From Investing Activities	-16.40M	-16.20M	62.80M
Cash From Financing Activities	1.200M	700.0K	1.600M
Net Change In Cash	-36.00M	-54.40M	24.90M
YoY Change	-244.58%	-196.63%	5.96%
FREE CASH FLOW
Cash From Operating Activities	-$20.80M	-$38.90M	-$39.50M
Capital Expenditures	-$6.800M	-$4.100M	-$28.10M
Free Cash Flow	-$14.00M	-$34.80M	-$11.40M
YoY Change	22.81%	89.13%	-28.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Entity Central Index Key EntityCentralIndexKey	0001001233
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	54243000	USD
CY2018	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26516000	USD
	dei	Entity File Number EntityFileNumber	000-30171
	dei	Entity Registrant Name EntityRegistrantName	SANGAMO THERAPEUTICS, INC
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	68-0359556
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	78723000	USD
CY2019Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	51741000	USD
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Address Address Line1 EntityAddressAddressLine1	501 Canal Boulevard
	dei	Entity Address City Or Town EntityAddressCityOrTown	Richmond
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94804
	dei	City Area Code CityAreaCode	510
	dei	Local Phone Number LocalPhoneNumber	970-6000
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	SGMO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	115937618	shares
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114291000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140418000	USD
CY2019Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	2000000	USD
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	240561000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	259715000	USD
CY2019Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	680000	USD
CY2018Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	375000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21953000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4673000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4691000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5340000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	384176000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	410521000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	52789000	USD
CY2019Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1500000	USD
CY2018Q4	us-gaap	Minority Interest MinorityInterest	739000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	419328000	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3500000	USD
CY2019Q3	us-gaap	Assets Assets	640222000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	367257000	USD
CY2018Q4	us-gaap	Assets Assets	590395000	USD
CY2019Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	21965000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	640222000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23562000	USD
CY2019Q3	us-gaap	Goodwill Goodwill	38270000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	40044000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	77505000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7725000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3364000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	21457000	USD
CY2019Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	11024000	USD
CY2018Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	9490000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	47561000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	47564000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	80550000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	78511000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	87798000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	108273000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40609000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27689000	USD
CY2019Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6395000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6705000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5542000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1960000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	220894000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	223138000	USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	1158000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1022000	USD
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1084372000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	929632000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-661540000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-562696000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4901000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1440000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	419089000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	366518000	USD
CY2019Q3	us-gaap	Minority Interest MinorityInterest	239000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46633000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14918000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47577000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	590395000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21958000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32381000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-29248000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10993000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	51206000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	39803000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57615000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36288000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28810000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	107593000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	81612000	USD
	us-gaap	Operating Expenses OperatingExpenses	154226000	USD
	us-gaap	Operating Expenses OperatingExpenses	113993000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16241000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-106649000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-56378000	USD
CY2019Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	1887000	USD
CY2018Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	3398000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	6729000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	6708000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-27361000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-12843000	USD
	us-gaap	Profit Loss ProfitLoss	-99920000	USD
	us-gaap	Profit Loss ProfitLoss	-49670000	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-54000	USD
CY2018Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-179000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-27307000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-12843000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-99741000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-49670000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.90
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	115710000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	101725000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	110837000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	95165000	shares
	us-gaap	Profit Loss ProfitLoss	-49670000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4077000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4139000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-27361000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-12843000	USD
	us-gaap	Profit Loss ProfitLoss	-99920000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49628000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	445748000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-49628000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-54000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-179000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31443000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	704000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4701000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-59000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-87000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	678000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	42000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-31497000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-12930000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-103381000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12930000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-103202000	USD
CY2019Q3	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	321000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	7000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	4077000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-59000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-27361000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	419328000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	367257000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3363000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1139000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	136308000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14091000	USD
	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	321000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	25000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	4139000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	678000	USD
	us-gaap	Profit Loss ProfitLoss	-99920000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	419328000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	387867000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1159000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3810000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-87000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-12843000	USD
	us-gaap	Profit Loss ProfitLoss	-49670000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1851000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	29000	USD
	sgmo	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-3796000	USD
CY2018Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	379906000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	187900000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	13696000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-715000	USD
	sgmo	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1753000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	690000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	215757000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10374000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	42000	USD
CY2018Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	379906000	USD
	us-gaap	Profit Loss ProfitLoss	-99920000	USD
	us-gaap	Profit Loss ProfitLoss	-49670000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2742000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1668000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3715000	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	305000	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	443000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17280000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2225000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4734000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	4043000	USD
	sgmo	Gain On Free Shares GainOnFreeShares	488000	USD
	sgmo	Gain On Free Shares GainOnFreeShares	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14091000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10374000	USD
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-218000	USD
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	789000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1608000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1127000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-20477000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	118540000	USD
	sgmo	Increase Decrease In Long Term Portion Of Lease Liabilities IncreaseDecreaseInLongTermPortionOfLeaseLiabilities	-920000	USD
	sgmo	Increase Decrease In Long Term Portion Of Lease Liabilities IncreaseDecreaseInLongTermPortionOfLeaseLiabilities	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	3580000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1730000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-123586000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	76711000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	321390000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	451239000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	292147000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	230547000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13894000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15028000	USD
	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	262000	USD
	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	0	USD
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	USD
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	5221000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	215757000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	388000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43399000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-240941000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	119239000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4257000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	136308000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5813000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	29647000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	65913000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143918000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53326000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117791000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	83000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4890000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14469000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	140810000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	230143000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26127000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. In March 2019, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (“Pfizer”). This adjustment was a direct result of the increase in project scope during the first quarter of 2019 and the corresponding costs which resulted in a decrease in the measure of proportional performance. This adjustment decreased revenue by </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, increased net loss by </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and increased the Company’s basic net loss per share by </span><span style="font-family:inherit;font-size:10pt;"><span>$0.03</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations. The Company reclassified </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> from Intangible assets to Other non-current assets on the Condensed Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company’s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div>
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	78723000	USD
CY2018Q4	sgmo	Deferred Rent Noncurrent DeferredRentNoncurrent	271000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-562696000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2019Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	3500000	USD
CY2019Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3500000	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	79941000	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114291000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140418000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39298000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49826000	USD
CY2019Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2000000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3500000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117791000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143918000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	119239000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53326000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	292931000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	421000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	293350000	USD
CY2019Q3	sgmo	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	370144000	USD
CY2019Q3	sgmo	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax	421000	USD
CY2019Q3	sgmo	Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax	2000	USD
CY2019Q3	sgmo	Cash Equivalents And Available For Sale Securities CashEquivalentsAndAvailableForSaleSecurities	370563000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	259974000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	259000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	259715000	USD
CY2018Q4	sgmo	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	363265000	USD
CY2018Q4	sgmo	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax	0	USD
CY2018Q4	sgmo	Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax	259000	USD
CY2018Q4	sgmo	Cash Equivalents And Available For Sale Securities CashEquivalentsAndAvailableForSaleSecurities	363006000	USD
CY2018Q3	sgmo	Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber	8770775	shares
CY2019Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	240561000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	259715000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	52789000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	0	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	293350000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	259715000	USD
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	USD
	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2019Q3	sgmo	Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber	10370481	shares
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2600000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	5300000	USD
CY2019Q3	us-gaap	Variable Lease Cost VariableLeaseCost	600000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	1200000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	2000000.0	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1073000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6055000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6097000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6165000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	6243000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	31946000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	57579000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13976000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	43603000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2994000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40609000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	43603000	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y1M6D
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.069
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4701000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3810000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14091000	USD
CY2018Q4	us-gaap	Minority Interest MinorityInterest	739000	USD
	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	321000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-179000	USD
CY2019Q3	us-gaap	Minority Interest MinorityInterest	239000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10374000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD

Files In Submission

Name	View Source	Status
0001628280-19-013510-index-headers.html	Edgar Link	pending
0001628280-19-013510-index.html	Edgar Link	pending
0001628280-19-013510.txt	Edgar Link	pending
0001628280-19-013510-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
sgmo-20190930.xsd	Edgar Link	pending
sgmo-20190930x10q.htm	Edgar Link	pending
sgmo-20190930x10q_htm.xml	Edgar Link	completed
sgmo-20190930xex101.htm	Edgar Link	pending
sgmo-20190930xex311.htm	Edgar Link	pending
sgmo-20190930xex312.htm	Edgar Link	pending
sgmo-20190930xex321.htm	Edgar Link	pending
sgmo-20190930_cal.xml	Edgar Link	unprocessable
sgmo-20190930_def.xml	Edgar Link	unprocessable
sgmo-20190930_lab.xml	Edgar Link	unprocessable
sgmo-20190930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SGMO
Sangamo Therapeutics Inc Stock $sgmo

2019 Q4 Form 10-Q Financial Statement

#000162828019013510 Filed on November 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGMO Sangamo Therapeutics Inc Stock $sgmo

2019 Q4 Form 10-Q Financial Statement

#000162828019013510 Filed on November 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGMO
Sangamo Therapeutics Inc Stock $sgmo